
Today on Drug Discovery & Development
From cost advantage to value advantage: The next frontier for generic manufacturers
For more than three decades, generic drugmakers competed on a simple formula: enter fast, manufacture at scale and cut costs. Generics and biosimilars saved the U.S. healthcare system $496 billion in 2025, according to the Association for Accessible Medicines’ 2026 savings report. That formula is now under strain. Purchasers have consolidated, prices face pressure, much…FDA approved Inovio’s Voceryq with open questions about its delivery device
The FDA has asked Inovio Pharmaceuticals, a company developing DNA-based medicines, to reanalyze its human factors testing of the Cellectra 5PSP, the electroporation device that delivers its newly approved drug Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), a pioneering plasmid DNA-based immunotherapy. The agency is also asking it to verify the device’s sharps injury prevention feature.…Drug Discovery and Development See More >

2026 PharmSci 360 adds tracks on research credibility and post-animal drug development
The Arlington, Virginia–based nonprofit American Association of Pharmaceutical Scientists (AAPS) will launch two Innovator-Curated tracks at its 2026 PharmSci 360 conference, scheduled for October 25–28, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The organization announced that the tracks will explore the current state of scientific research integrity in an AI…

FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide

As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%

Sai Life Sciences’ bet on information-dense scale-up and how it is responding to pharma clients who want acceleration

Ahead of PharmSci 360, DigiM CEO on turning hidden microstructures into drug-release predictions
Sponsored Content See More >
Genomics/Proteomics See More >

New cell imaging method reveals hidden enzyme activity
Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the optical readout of…

Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification

Spatial biology: Transforming our understanding of cellular environments

Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Infectious Disease See More >

Moderna, Merck move toward filing for personalized melanoma therapy as COVID sales lift Q3
Moderna is preparing to seek approval for intismeran autogene, the personalized cancer vaccine it is developing with Merck, according to its November 6 earnings release. The therapy could open a new source of revenue beyond the infectious disease vaccines that built its business. Investor enthusiasm has rebounded as the cancer program has advanced. Moderna shares…

Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice

AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.

FDA greenlights ViiV’s Tivicay PD for HIV-positive newborns in first month of life

As measles cases hit a 35-year high, Trump executive order backs a narrower childhood vaccine list
Oncology See More >

What real-world data shows about current cancer care
Only about 5% of adult cancer patients join clinical trials. Experts explain how real-world data fills gaps and what makes it representative and reliable.

Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront

After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice

Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice

























